Scienture Holdings, Inc.

Contributing Author

Recent Articles by Scienture Holdings, Inc.

Aug-14	SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance SCNX GlobeNewswire
Aug-12	SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY, the Highest Dose FDA-Approved Naloxone Nasal Spray SCNX +10.00% GlobeNewswire
Jul-09	SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY (naloxone hydrochloride) to Wholesalers SCNX GlobeNewswire
Jun-18	SCIENTURE Expands Arbli Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide SCNX GlobeNewswire
Jun-09	SCIENTURE Secures Formulary Coverage for REZENOPY with a Large National Health Plan and Expands Commercial Team SCNX GlobeNewswire
Jun-02	SCIENTURE Receives U.S. Patent Covering REZENOPY (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 SCNX GlobeNewswire
May-18	SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion SCNX GlobeNewswire
May-07	Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline SCNX +8.64% GlobeNewswire
May-06	SCIENTURE Announces Third Patent Grant for ARBLI (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041 SCNX GlobeNewswire
Apr-15	Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement SCNX +16.68% GlobeNewswire
Apr-06	Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead SCNX +10.26% GlobeNewswire
Mar-30	SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update SCNX -42.23% GlobeNewswire
Mar-11	SCIENTURE Broadens Commercial Access for REZENOPY, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions SCNX +19.46% GlobeNewswire
Feb-03	SCIENTURE Provides Commercial Update on ARBLI, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium SCNX GlobeNewswire
Jan-14	SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment SCNX GlobeNewswire
Dec-22	SCIENTURE Provides Update on the Commercial Launch of REZENOPY, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA SCNX -8.61% GlobeNewswire
Dec-10	SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium SCNX GlobeNewswire
Dec-02	SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9-10, 2025 SCNX GlobeNewswire
Nov-13	SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update SCNX -5.47% GlobeNewswire
Nov-04	SCIENTURE Announces Addition of Arbli (Losartan Potassium) to Formularies of Major National Health Plans SCNX +15.35% GlobeNewswire
Oct-23	SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli (Losartan Potassium) SCNX +354.94% GlobeNewswire
Oct-16	SCIENTURE'S Arbli Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers SCNX -17.63% GlobeNewswire
Oct-08	SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet SCNX GlobeNewswire
Oct-01	SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli (losartan potassium) to more than 2500 Healthcare Institutions SCNX GlobeNewswire
Sep-16	SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli(losartan potassium) in the $256M U.S. Losartan Market SCNX GlobeNewswire
Aug-14	Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock SCNX -45.50% GlobeNewswire
Aug-13	SCIENTURE announces the shipment of launch quantities of Arbli (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones. SCNX +6.22% GlobeNewswire
Jul-24	Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding SCNX -5.58% GlobeNewswire
Jul-16	Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements SCNX +19.88% GlobeNewswire
Jun-17	Scienture Holdings Announces Cancelation of ELOC SCNX -8.57% GlobeNewswire
May-22	SCIENTURE Announces Executive Leadership Transition SCNX GlobeNewswire
May-19	SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. SCNX +6.51% GlobeNewswire

Scienture Holdings, Inc.

Recent Articles by Scienture Holdings, Inc.

Upgrade your Finviz experience